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was associated with an elevated risk of adverse cardiovascular events and mortality.
Although inextricable links exist between obesity, type-2 diabetes and cardiovascular
disease in the general population, the extent to which ﬁ ndings can be extrapolated to 
a diabetes-speciﬁ c population is limited.
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OBJECTIVES: This study evaluated real world outcomes for type 2 diabetes (T2D)
patients treated with analog basal insulin (glargine or detemir) on glycemic control and 
weight after 6 months in a national electronic medical record (EMR) database.
METHODS: Patient data were extracted from the General Electric (GE) EMR database 
from January 1, 2000 through December 31, 2007. Patients were q18 years old with 
T2D deﬁ ned by ICD-9 codes, q2 fasting blood glucose levels q126 mg/dL, or A1C 
7.0%. Patients had prescription orders in the previous 395 days for metformin, a sul-
fonylurea or a thiazolidinedione, alone or in combination, or had no prior antidiabetic 
treatment. Patients were initiated on a basal insulin with no prior insulin use, had no
other insulin prescribed within six months of basal insulin initiation, and had at least
one additional order for the prescribed basal insulin within six months. Baseline A1C
and weight were documented a45 days prior to q15 days post basal insulin initiation
and at six months post initiation o 45 days. RESULTS: Of patients with 6 month A1C
or weight follow-up data (n  841 and n  1817, respectively), mean (oSD) baseline 
A1C was 9.0 o 1.9% and weight was 99 o 25.0 kg. Mean BMI was 34.7 o 8.1 kg/m2. 
The majority were treated with insulin glargine (n  1754; 91.2%). At six months mean
(SEM) A1C reduction was 1.2(0.1)% with 20.0% (n  393) achieving A1C goal of 
7.0%;. Mean weight gain was 1.0(0.1) kg (p  .001) and 60% (n  1103) of patients
gained weight. CONCLUSIONS: In a real world setting, most patients (80%) did not
reach ADA targets for glycemic control with analog basal insulin treatment. Addition-
ally, the majority of patients (60%) experienced weight gain.
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OBJECTIVES: Sustained-release glipizide has a more appealing pharmacological
proﬁ le over immediate-release glipizides. However, individual trials have not reliably 
ascertained its effects. This study systematically reviewed the trials that compared the 
effects of sustained-release glipizide with the conventional immediate-release glipizide 
for type 2 diabetes mellitus. METHODS: We searched Medline, EMBASE, the 
Cochrane Library and three other Chinese databases from their inception to July 2008, 
as well as screened the reference lists of eligible trials and reviews, and contacted the 
company (Pﬁ zer) for unpublished data. Two reviewers judged the trial eligibility,
assessed the validity, and extracted data independently. We pooled the trial data using
the random-effect model and explored the heterogeneity by the pre-speciﬁ ed variables.
RESULTS: A total of 16 trials (n  1033) were included. Sustained-release glipizide 
signiﬁ cantly decreased FPG by 0.33mmol/L (weighted mean difference, 95%CI 0.05
to 0.61), postprandial insulin levels by 3. ìIU/ml (0.89 to 5.47), and C-peptide by 
0.12 ng/ml (0.04 to 0.20). Sustained-release glipizide did not reduced the HbA1c 
(0.02, 0.20 to 0.15), postprandial plasma glucose (0.38, 0.47 to 1.22), fasting 
insulin levels (1.20, 0.14 to 2.54). No statistical differences were found in the change 
of total cholesterol (0.09, 0.06 to 0.23), triglyceride (0.13, 0.04 to 0.29), LDL
(0.03, 0.12 to 0.05), HDL(0.04, 0.02 to 0.10), and hypoglycemia (RR 0.79,
95%CI 0.22 to 2.86). No trials reported diabetes-related morbidity and mortality.
CONCLUSIONS: Sustained-release glipizide could reduce FPG, postprandial insulin
levels, and C-peptide, but has not shown beneﬁ ts in reducing HbA1c, PPG, and fasting 
insulin levels when compared to immediate-release glipizide. Uncertainty remained in
the beneﬁ ts of sustained-release glipizide over immediate-release glipizide. This was 
mainly driven by the small sample size of the trial and lack of long-term morbidity 
and mortality data.
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OBJECTIVES: This study was conducted to determine the usefulness of metformin 
therapy in improving outcomes related to infertility in patients with polycystic ovary 
syndrome (PCOS). A Bayesian meta-analytic and mixed treatment comparison (MTC) 
approach was used. METHODS: An electronic literature search was performed using 
PubMed and the Cochrane Central Register of Controlled Trials to identify random-
ized controlled trials that reported at least one of the outcomes of interest – ovulation,
pregnancy and live birth in PCOS patients randomized to treatment with either met-
formin, clomiphene citrate (CC) or combination of these drugs, which included a 
comparison with either placebo or each other. Reference lists of meta-analyses and 
reviews were hand searched to identify any additional articles. Bayesian meta-analyses 
were conducted for each outcome separately and for different therapeutic comparisons 
with metformin. Additionally, Bayesian MTCs were also conducted for each outcome.
Analyses were performed using random effects models. RESULTS: A total of 27 RCTs
were identiﬁ ed and 24 studies reported outcomes in a usable form for inclusion in the 
analysis. The total number of patients was 2217. The meta-analyses revealed that 
metformin was superior to placebo for ovulation induction (median OR  2.9 with 
95%[CrI] 1.6–6.0). Comparison of metformin and CC to CC alone revealed that
combination therapy was superior in both ovulation induction (median OR  4.2 with 
95%[CrI] 1.5–12.3) and pregnancy (median OR  5.0 with 95%[CrI] 1.7–22.4).
When live birth was considered there was no signiﬁ cant difference between combina-
tion therapy and CC alone (median OR  2.2 with 95%[CrI] 0.4–55.5). In the MTC, 
the efﬁ cacy of the therapeutic comparisons for ovulation and pregnancy in descending 
ranking order was combination therapy, CC alone, metformin alone and placebo.
CONCLUSIONS: Combination therapy with metformin and CC is more effective than 
CC alone in ovulation and pregnancy outcomes in women with PCOS.
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OBJECTIVES: The aim of this review was to assess whether lifestyle education pro-
grams signiﬁ cantly improve glucose levels or lower the incidence of type-2 diabetes in
people at high risk, compared with conventional education programs. METHODS:
English language trials assessing lifestyle interventions (physical exercise, diet control 
and counselling programs) compared to usual care controls were searched via elec-
tronic databases. Two investigators independently reviewed abstracts and included
studies in which subjects had impaired glucose tolerance, impaired fasting glucose or
borderline values. Data was extracted from each included full-text publication. The 
outcomes of interest included change in glucose levels two hours after a 75g oral
glucose load, change in fasting plasma glucose levels, and cumulative diabetes inci-
dence during the intervention period. RESULTS: Eleven citations met the eligibility 
criteria, out of 198 retrieved from the databases. Of these, only four presented sufﬁ -
cient data for meta-analysis. Meta-analysis of two studies indicated that the decrease 
from baseline in 2-hour plasma glucose was signiﬁ cantly greater in the lifestyle inter-
vention group than in the control group (WMD  11.292 mg/dL, 95% CI: 17.718, 
4.866). Results were similar for fasting plasma glucose, with a ﬁ xed-effects meta-
analyses of data from the same two studies showing a signiﬁ cantly greater decrease
from baseline in the intervention group compared to control (ﬁ xed effects WMD 
2.158 mg/dL, 95% CI: 4.239, 0.077). Meta-analysis of two other studies indicated
that the cumulative diabetes incidence in the lifestyle intervention group was signiﬁ -
cantly lower than in the control group (ﬁ xed effects RR  0.619, 95% CI: 0.522,
0.733). CONCLUSIONS: Structured lifestyle interventions involving a healthy diet 
and physical activity are an effective way to treat, prevent, and possibly delay type-2
diabetes. If lifestyle interventions are cost-effective from a health system perspective,
they should be more frequently considered as a valid treatment option.
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OBJECTIVES: Six-month real-world outcomes were previously reported for exena-
tide, a GLP-1 receptor agonist for the treatment of type- 2 diabetes (T2D). A1C 
reductions were 0.7%, weight reductions were 2.8 kg, and BMI reductions were 
0.94 kg/m2. The current 18 month analysis evaluated A1C, weight, and BMI out-
comes to establish real-world durability of glycemic control and weight loss in patients 
using exenatide. METHODS: Data were extracted from the General Electric electronic 
medical record database from January 1, 2000 to December 31, 2007. Adults with
T2D per ICD-9 codes, q2 fasting blood glucose levels q126 mg/dL, or A1C  7.0% 
starting exenatide in or after 2005 were included. Patients had 2 additional prescrip-
tion orders including at least one 12 to 18 months after the initial prescription to 
indicate ongoing therapy, and had prior prescription orders for metformin, a sulfo-
nylurea, or a thiazolidinedione alone or in combination. A1C, weight and BMI were
documented at exenatide initiation (45 to  15d) and at 18 months (o45 d). Out-
comes were evaluated in those with baseline and follow-up A1C, weight and BMI
measures. RESULTS: In 102 study patients, baseline A1C was 8.21.1%, weight was
111 o 12.3 kg. Baseline BMI was 38.6q o 7.4 kg/m2 in those with baseline and follow 
up data (n  89). After 18 months of exenatide therapy, mean (oSEM) A1C decrease 
was 0.7(o0.2)% (p  .001), weight decrease was 4.7(o0.7) kg (p  .001), and BMI 
decrease was 0.8 (o0.3) kg/m2 (p  .001). A total of 72.0% had an A1C reduction, 
76.7% lost weight, and 57.0% had reductions in A1C and weight. Mean A1C reduc-
tion was identical and weight loss was approximately 2 kg greater at 18 months rela-
tive to 6 month cohort exenatide outcomes. CONCLUSIONS: Exenatide therapy was 
associated with signiﬁ cant reductions in A1C, weight and BMI at 18 months. These 
reductions demonstrate treatment durability with exenatide and continuous beneﬁ t 
from long term therapy.
